Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (5): 845-850. doi: 10.19723/j.issn.1671-167X.2020.05.008
Previous Articles Next Articles
CLC Number:
[1] |
Grieger JC, Choi VW, Samulski RJ. Production and characterization of adeno-associated viral vectors [J]. Nat Protoc, 2006,1(3):1412-1428.
doi: 10.1038/nprot.2006.207 pmid: 17406430 |
[2] |
Berns KI, Nicholas M. AAV: An overview of unanswered questions[J]. Hum Gene Ther, 2017,28(4):308-313.
doi: 10.1089/hum.2017.048 pmid: 28335618 |
[3] |
Alves CH, Wijnholds J. AAV gene augmentation therapy for CRB1-associated retinitis pigmentosa[J]. Methods Mol Biol, 2018,1715:135-151.
pmid: 29188511 |
[4] |
Moore NA, Morral N, Ciulla TA. Gene therapy for inherited retinal and optic nerve degenerations[J]. Expert Opin Biol Ther, 2018,18(1):37-49.
doi: 10.1080/14712598.2018.1389886 pmid: 29057663 |
[5] |
Sullivan JA, Stanek LM, Lukason MJ. Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain[J]. Gene Ther, 2018,25(3):205-219.
doi: 10.1038/s41434-018-0017-8 pmid: 29785047 |
[6] |
Ong T, Pennesi ME, Birch DG. Adeno-Associated viral gene therapy for inherited retinal disease[J]. Pharm Res, 2019,36(2):34.
doi: 10.1007/s11095-018-2564-5 pmid: 30617669 |
[7] |
Russell S, Bennett J, Wellman JA. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2017,390(10097):849-860.
doi: 10.1016/S0140-6736(17)31868-8 pmid: 28712537 |
[8] |
Hung SC, Chrysostomou V, Li F. AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo[J]. Invest Ophthalmol Vis Sci, 2016,57(7):3470-3476.
doi: 10.1167/iovs.16-19316 pmid: 27367513 |
[9] |
Day TP, Byrne LC, Schaffer DV, et al. Advances in AAV vector development for gene therapy in the retina[J]. Adv Exp Med Biol, 2014,801:687-693.
doi: 10.1007/978-1-4614-3209-8_86 |
[10] |
Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel Adeno-associated virus serotypes efficiently transduce murine photoreceptors[J]. J Virol, 2007,81(20):11372-11380.
doi: 10.1128/JVI.01327-07 pmid: 17699581 |
[11] |
Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer[J]. Vision Res, 2008,48(3):353-359.
doi: 10.1016/j.visres.2007.07.027 |
[12] |
Bennett J, Wellman J, Marshall KA. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial[J]. Lancet, 2016,388(10045):661-672.
doi: 10.1016/S0140-6736(16)30371-3 pmid: 27375040 |
[13] |
Carvalho LS, Xu J, Pearson RA, et al. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy[J]. Hum Mol Genet, 2011,20(16):3161-3175.
doi: 10.1093/hmg/ddr218 |
[14] |
Flannery JG, Zolotukhin S, Vaquero MI. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus[J]. Proc Natl Acad Sci USA, 1997,94(13):6916-6921.
doi: 10.1073/pnas.94.13.6916 pmid: 9192666 |
[15] |
Young JE, Vogt T, Gross KW, et al. A short, highly active photoreceptor-specific enhancer/promoter region upstream of the human rhodopsin kinase gene[J]. Invest Ophthalmol Vis Sci, 2003,44(9):4076-4085.
doi: 10.1167/iovs.03-0197 pmid: 12939331 |
[16] |
Nicoletti A, Kawase K, Thompson DA. Promoter analysis of RPE65, the gene encoding a 61-kDa retinal pigment epithelium-specific protein[J]. Invest Ophthalmol Vis Sci, 1998,39(3):637-644.
pmid: 9501877 |
[17] |
Esumi N, Oshima Y, Li Y, et al. Analysis of the VMD2 promoter and implication of E-box binding factors in its regulation[J]. J Biol Chem, 2004,279(18):19064-19073.
doi: 10.1074/jbc.M309881200 pmid: 14982938 |
[18] |
Corti M, Liberati C, Smith BK. Safety of intradiaphragmatic deli-very of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease[J]. Hum Gene Ther Clin Dev, 2017,28(4):208-218.
doi: 10.1089/humc.2017.146 pmid: 29160099 |
[19] |
Martier R, Sogorb-Gonzalez M, Stricker-Shaver J. Development of an AAV-based MicroRNA gene therapy to treat Machado-Joseph disease[J]. Mol Ther Methods Clin Dev, 2019,15:343-358.
doi: 10.1016/j.omtm.2019.10.008 pmid: 31828177 |
[1] | JIA Rui-xuan,JIANG Shang-wei,ZHAO Lin,YANG Li-ping. Generation and characterization of Cyp4v3 gene knockout mice [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1099-1106. |
[2] | Xiao-zhen LIU,Ying-ying LI,Li-ping YANG. Comparison study of whole exome sequencing and targeted panel sequencing in molecular diagnosis of inherited retinal dystrophies [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 836-844. |
|